Eric Rivas1,2, Joshua S Wooten3, Daniel E Newmire4, Vic Ben-Ezra4. 1. Exercise Physiology and Biochemistry Laboratory, Department of Kinesiology, Texas Woman's University, Denton, TX, USA. erivas4@uci.edu. 2. Institute for Clinical and Translational Science & Department of Pediatrics, The University of California, Irvine, CA, USA. erivas4@uci.edu. 3. Department of Kinesiology and Health Education, Southern Illinois University Edwardsville, Edwardsville, IL, USA. 4. Exercise Physiology and Biochemistry Laboratory, Department of Kinesiology, Texas Woman's University, Denton, TX, USA.
Abstract
PURPOSE: The aim of this study was to determine if omega-3 (n-3) supplementation combined with acute aerobic exercise would improve glucose and insulin responses in normoglycemic, inactive, overweight men. METHODS: In a random order, ten inactive and normoglycemic men (30.6 ± 10 years, 85.4 ± 11 kg, 26.7 ± 4 BMI) completed a rest (R) and exercise trial (EX) without n-3 supplementation. Following 42 days of n-3 supplementation, participants again completed a rest (R + n-3) and exercise trial (EX + n-3) with continued n-3 supplementation. The exercise trial consisted of 3 days of ~70 % VO2peak for 60 min/session. N-3 supplementation entailed 4.55 g/day of n-3 (EPA 2.45 g, DHA 1.61 g). A 75g oral glucose tolerance (OGTT) test was administered 14-16 h after each trial. RESULTS: Relative to R (35,278 ± 9169 pmol/L), EX without n-3 reduced the incremental area under the curve for insulin (iAUCinsulin) during an OGTT by 21.3 % (27765 ± 4925 pmol/L, p = 0.018) and 20.6 % after the EX + n-3 trial (27,999 ± 8370 pmol/L; p = 0.007). In addition, EX (96 ± 21 pmol/L; p = 0.006) reduced C-peptide by 13.5 % when compared to R (111 ± 26 pmol/L). No difference was observed between R and n-3 trials for iAUCinsulin and iAUCC-peptide. Only EX improved insulin sensitivity index by 5.6 % (p = 0.02) when compared to R. CONCLUSIONS: These data suggest that n-3 supplementation does not add any additional benefit beyond the exercise induced insulin responses in inactive men. Furthermore, n-3 supplementation alone does not appear to impair insulin action in normoglycemic, inactive, overweight men.
RCT Entities:
PURPOSE: The aim of this study was to determine if omega-3 (n-3) supplementation combined with acute aerobic exercise would improve glucose and insulin responses in normoglycemic, inactive, overweight men. METHODS: In a random order, ten inactive and normoglycemic men (30.6 ± 10 years, 85.4 ± 11 kg, 26.7 ± 4 BMI) completed a rest (R) and exercise trial (EX) without n-3 supplementation. Following 42 days of n-3 supplementation, participants again completed a rest (R + n-3) and exercise trial (EX + n-3) with continued n-3 supplementation. The exercise trial consisted of 3 days of ~70 % VO2peak for 60 min/session. N-3 supplementation entailed 4.55 g/day of n-3 (EPA 2.45 g, DHA 1.61 g). A 75 g oral glucose tolerance (OGTT) test was administered 14-16 h after each trial. RESULTS: Relative to R (35,278 ± 9169 pmol/L), EX without n-3 reduced the incremental area under the curve for insulin (iAUCinsulin) during an OGTT by 21.3 % (27765 ± 4925 pmol/L, p = 0.018) and 20.6 % after the EX + n-3 trial (27,999 ± 8370 pmol/L; p = 0.007). In addition, EX (96 ± 21 pmol/L; p = 0.006) reduced C-peptide by 13.5 % when compared to R (111 ± 26 pmol/L). No difference was observed between R and n-3 trials for iAUCinsulin and iAUCC-peptide. Only EX improved insulin sensitivity index by 5.6 % (p = 0.02) when compared to R. CONCLUSIONS: These data suggest that n-3 supplementation does not add any additional benefit beyond the exercise induced insulin responses in inactive men. Furthermore, n-3 supplementation alone does not appear to impair insulin action in normoglycemic, inactive, overweight men.
Authors: A A Rivellese; A Maffettone; C Iovine; L Di Marino; G Annuzzi; M Mancini; G Riccardi Journal: Diabetes Care Date: 1996-11 Impact factor: 19.112
Authors: J Kang; R J Robertson; J M Hagberg; D E Kelley; F L Goss; S G DaSilva; R R Suminski; A C Utter Journal: Diabetes Care Date: 1996-04 Impact factor: 19.112
Authors: Joseph A Houmard; Charles J Tanner; Cris A Slentz; Brian D Duscha; Jennifer S McCartney; William E Kraus Journal: J Appl Physiol (1985) Date: 2003-09-12
Authors: John P Kirwan; Thomas P J Solomon; Daniel M Wojta; Myrlene A Staten; John O Holloszy Journal: Am J Physiol Endocrinol Metab Date: 2009-04-21 Impact factor: 4.310
Authors: Martin Rossmeisl; Zuzana Macek Jilkova; Ondrej Kuda; Tomas Jelenik; Dasa Medrikova; Barbora Stankova; Björn Kristinsson; Gudmundur G Haraldsson; Harald Svensen; Iren Stoknes; Peter Sjövall; Ylva Magnusson; Michiel G J Balvers; Kitty C M Verhoeckx; Eva Tvrzicka; Morten Bryhn; Jan Kopecky Journal: PLoS One Date: 2012-06-11 Impact factor: 3.240
Authors: Eric Rivas; David N Herndon; Craig Porter; Walter Meyer; Oscar E Suman Journal: Am J Physiol Endocrinol Metab Date: 2017-11-14 Impact factor: 4.310
Authors: Todd Castleberry; Christopher Irvine; Sarah E Deemer; Matthew F Brisebois; Ryan Gordon; Michael D Oldham; Anthony A Duplanty; Vic Ben-Ezra Journal: Eur J Appl Physiol Date: 2019-05-11 Impact factor: 3.078